Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.